Summary of Conference Call Company and Industry Overview - The discussion centers around **Alkermes**, a biopharmaceutical company focused on developing treatments for central nervous system disorders, particularly narcolepsy and other sleep-related conditions. The company is optimistic about its **orexin program** and its potential impact on the market in 2026 [2][3]. Core Insights and Arguments - **Positive Outlook**: Alkermes is experiencing a positive sentiment regarding its orexin program, especially with the anticipated approval of Takeda's drug, which is expected to set market pricing and demonstrate launch trajectories [2][3]. - **Differentiation Factors**: The key differentiators for Alkermes' drug compared to competitors will be **dosing flexibility** and the ability to treat various types of hypersomnolence without needing differential diagnoses [4][6]. - **Clinical Trial Insights**: In clinical trials, over 70% of patients reported normalcy on the **Epworth Sleepiness Scale (ESS)** at the highest dose, indicating strong efficacy. The company emphasizes the importance of various endpoints beyond the **Maintenance of Wakefulness Test (MWT)** [13][15]. - **Dosing Strategy**: Alkermes plans to offer a range of dosing options, including once-daily and split doses, to cater to patient needs and lifestyle preferences [5][6]. Additional Important Points - **Market Pricing Strategy**: The company is considering pricing strategies in a post-Inflation Reduction Act (IRA) environment, where orphan medications are priced between **$300,000-$400,000**. Alkermes aims to avoid setting a lower price outside the U.S. that could influence domestic pricing [46][47]. - **Expansion into Other Indications**: Alkermes is exploring additional indications for its orexin agonists, including **ADHD** and **fatigue** in conditions like **multiple sclerosis (MS)** and **Parkinson's disease**. The company believes there is a significant unmet clinical need in these areas [49][51]. - **Regulatory Pathways**: For fatigue, Alkermes is working with the FDA to establish a regulatory pathway, utilizing validated endpoints to capture clinical experiences [54][56]. - **LUMRYZ Acquisition**: The acquisition of LUMRYZ is seen as valuable, particularly for its indication in idiopathic hypersomnia (IH), which is expected to contribute to growth in the market [57][58]. - **Market Dynamics**: The narcolepsy market has approximately **200,000** patients in the U.S., with only **80,000** currently treated. The company anticipates that new effective oral medications will increase diagnosis rates and treatment uptake [61][62]. This summary encapsulates the key points discussed during the conference call, highlighting Alkermes' strategic positioning, product differentiation, and market opportunities.

Summary of Alkermes Conference Call Company Overview - **Company**: Alkermes - **Event**: 2026 TD Cowen Healthcare Conference - **Key Speaker**: Richard Pops, Chairman and CEO Industry Focus - **Primary Industry**: Sleep Medicine - **Key Products**: Alixorexton, LUMRYZ, Avadel acquisition Core Points and Arguments 1. **Business Transition**: Alkermes has undergone significant changes in 2025, solidifying its position in the sleep medicine market, particularly with the orexin franchise and the acquisition of Avadel [2][3] 2. **Market Position**: The company is now a major player in the sleep medicine market, preparing for the launch of alixorexton, supported by a strong and cash-generative base business [3] 3. **Acquisition Rationale**: The acquisition of Avadel was strategic, enhancing the company's presence in sleep centers and preparing for the alixorexton launch, which is expected to shift the launch curve positively [4][7] 4. **Unmet Needs in Narcolepsy**: There is a significant gap between the prevalence of narcolepsy (approximately 200,000 patients in the U.S.) and those treated (about 80,000), indicating a large market opportunity [15] 5. **Orexin Compounds**: The company is investigating the ideal dosing for orexin agonists, with promising data from Phase 2 studies indicating safety and efficacy [17][18] 6. **Phase 3 Program**: Alkermes is initiating a Phase 3 program with three studies focused on NT-1 and NT-2, with primary endpoints including the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) [24][25] 7. **Cognitive and Fatigue Outcomes**: The company has observed significant improvements in cognitive complaints and fatigue in patients, which are critical for treatment success [56][57] Additional Important Content 1. **Base Business Strength**: Alkermes has transformed from a royalty-based business to a proprietary products business, with expectations of $1.4 billion from proprietary products in 2026 [59][60] 2. **Commercial Strategy**: The acquisition of Avadel is expected to broaden the commercial portfolio and increase profitability, allowing for aggressive investment in the pipeline [60][61] 3. **Future Opportunities**: Alkermes is exploring additional indications for orexin drugs, including ADHD and fatigue, with initial proof of concept data expected soon [46][48] 4. **Side Effect Profile**: The orexin compounds have a mild to moderate side effect profile, with insomnia being the most common, which tends to diminish over time [39][40] 5. **Business Development**: The company is open to tuck-in business development deals that leverage its clinical and scientific capabilities but is currently focused on executing its late-stage and earlier-stage programs [63][64] This summary encapsulates the key points discussed during the conference call, highlighting Alkermes' strategic direction, market opportunities, and product development plans.

Core Viewpoint - Alkermes is positioning itself for growth in 2026 following a strong performance in 2025, with a focus on expanding its commercial platform and advancing its orexin pipeline, particularly through the recent acquisition of Avadel and the development of alixorexton [5][21]. Financial Performance - For 2025, Alkermes reported GAAP net income of $241.7 million and adjusted EBITDA of $394.0 million, ending the year with $1.3 billion in cash and total investments [2]. - Total revenues for 2025 were nearly $1.5 billion, driven by proprietary product net sales of approximately $1.2 billion, which grew 9% year over year [4]. Revenue Guidance for 2026 - Alkermes guided total revenues for 2026 between $1.73 billion and $1.84 billion, with proprietary product net sales expected to be between $1.52 billion and $1.60 billion [1]. - Manufacturing and royalty revenues are projected to be between $210 million and $240 million, reflecting the expiration of certain XEPLION royalties [1]. Expense Management - Cost of goods sold for 2026 is expected to be between $365 million and $385 million, influenced by purchase price accounting for LUMRYZ inventory [6]. - R&D expenses are projected to be between $445 million and $485 million, while SG&A expenses are expected to be between $890 million and $930 million, including one-time transaction costs related to the Avadel acquisition [7]. Product Performance - VIVITROL net sales for 2025 were $467.9 million, with a guidance of $460 million to $480 million for 2026 [10]. - ARISTADA net sales were $370.0 million in 2025, with a guidance of $365 million to $385 million for 2026 [11]. - LYBALVI saw a 24% increase in net sales to $346.7 million in 2025, with a guidance of $380 million to $400 million for 2026 [12]. - LUMRYZ generated approximately $279 million in net sales in 2025, with a guidance of $350 million to $370 million for 2026 [13]. Pipeline Developments - Alixorexton is expected to enter phase III trials in narcolepsy, with a detailed program planned [15][16]. - The company is also advancing two additional orexin 2 receptor agonists in phase I studies, with plans for further development in ADHD and fatigue associated with multiple sclerosis and Parkinson's disease [18]. Leadership Transition - A leadership transition is underway, with CEO Richard Pops set to step down and COO Blair Jackson taking over, while Pops will remain as chairman [21].

Financial Data and Key Metrics Changes - In 2025, total revenues reached nearly $1.5 billion, with a year-over-year growth of 9% driven primarily by proprietary products generating approximately $1.2 billion in net sales [9][10] - GAAP net income for the year was $241.7 million, with adjusted EBITDA of $394 million [11][18] - The company ended the year with $1.3 billion in cash and total investments [12] Business Line Data and Key Metrics Changes - VIVITROL net sales were $467.9 million, reflecting a 2% growth year-over-year [24] - ARISTADA net sales reached $370 million, showing a 7% growth year-over-year [26] - LYBALVI net sales grew 24% year-over-year to $346.7 million [27] - LUMRYZ generated approximately $279 million in net sales in 2025, with around 3,500 patients on therapy by year-end [30] Market Data and Key Metrics Changes - The company expects total revenues for 2026 to be in the range of $1.73 billion to $1.84 billion, driven primarily by proprietary products [13][14] - Manufacturing and royalty revenues for 2026 are anticipated to be between $210 million and $240 million [15] - The estimated market for oxybate-eligible patients with narcolepsy is around 50,000, indicating significant growth potential for LUMRYZ [32] Company Strategy and Development Direction - The acquisition of Avadel is seen as a strategic milestone, enhancing the company's entry into the commercial sleep medicine market and providing a platform for launching alixorexton [6][12] - The company plans to initiate the phase III Brilliance program for alixorexton in narcolepsy, with expectations of significant advancements in treatment [34] - The focus remains on operational discipline, efficient capital allocation, and investing in high-potential growth drivers, particularly in the orexin portfolio [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong financial position and the potential for growth in 2026, emphasizing the importance of the Avadel acquisition [12][23] - The company is committed to delivering shareholder growth and maintaining a strong cash flow positive profile despite expected GAAP net losses due to accounting for the acquisition [18] - Management highlighted the importance of ongoing clinical trials and the potential for alixorexton to transform narcolepsy management [40] Other Important Information - The company plans to initiate a multi-dose phase Ib study for ALKS 7290 in ADHD and a phase IIa study for ALKS 4510 in fatigue associated with neurodegenerative disorders [38][39] - The transition of CEO leadership from Richard Pops to Blair Jackson is set to occur in the summer, with Pops continuing as chairman [40] Q&A Session Summary Question: Phase III trial design and AE profile - Management indicated that the orexin 2 receptor agonists are generally well tolerated, and the split dosing is designed to maximize efficacy while minimizing side effects [44][46] Question: Potential synergies from Avadel acquisition - The integration of the Avadel commercial team is progressing well, with expectations of future synergies as the company prepares to launch alixorexton [48][49] Question: Evidence needed for payer reimbursement for both oxybates and orexin agonists - Management believes that both treatments will be important for certain patients, and they plan to generate data to support reimbursement for this cohort [51][52] Question: Internal bar for ESS in LUMRYZ phase III - Management expects the data from the IH study to mirror previous successful programs, with key secondaries being important for prescriber confidence [56][60] Question: Current understanding of NT1 versus NT2 and IH dynamics - Management noted that the narcolepsy market represents a significant opportunity, with ongoing efforts to understand the IH market better [66]

Financial Data and Key Metrics Changes - In 2025, Alkermes generated total revenues of nearly $1.5 billion, with a year-over-year growth of 9% driven primarily by proprietary products, which generated approximately $1.2 billion in net sales [9][10] - GAAP net income for the year was $241.7 million, with EBITDA of $285.6 million and adjusted EBITDA of $394 million [11] - The company ended the year with $1.3 billion in cash and total investments [12] Business Line Data and Key Metrics Changes - VIVITROL net sales were $467.9 million, ARISTADA net sales were $370 million, and Lybalvi net sales were $346.7 million for 2025 [9][10] - For 2026, total revenues are expected to be in the range of $1.73 billion to $1.84 billion, primarily driven by proprietary products [13] - LUMRYZ, launched in 2023, generated approximately $279 million in net sales in 2025, with expectations of $350 million to $370 million for 2026 [27][30] Market Data and Key Metrics Changes - The company anticipates manufacturing and royalty revenues in the range of $210 million to $240 million for 2026, reflecting the expiration of certain XEPLION royalties [14] - The estimated market for narcolepsy includes about 200,000 patients in the US, with approximately 80,000 currently being treated [63] Company Strategy and Development Direction - The acquisition of Avadel is seen as a strategic step to enter the commercial sleep medicine market and enhance the company's product portfolio [6][12] - The company plans to advance its orexin portfolio, including alixorexton, which is expected to enter Phase 3 trials for narcolepsy [7][31] - The focus remains on operational discipline, efficient capital allocation, and investing in long-term growth opportunities [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong financial position and the potential for growth in 2026, despite anticipated GAAP net losses due to accounting related to the Avadel acquisition [17] - The company is committed to delivering shareholder growth and maintaining a strong cash flow positive profile [20][21] Other Important Information - The transition of CEO from Richard Pops to Blair Jackson is planned for summer 2026, with Pops continuing as chairman [38] - The company is focused on integrating the Avadel team and leveraging their expertise in sleep medicine [29] Q&A Session Summary Question: Phase 3 trial design and AE profile - Management indicated that the orexin 2 receptor agonists have a favorable AE profile and that split dosing is designed to maximize efficacy while minimizing side effects [42][43] Question: Potential synergies across sales forces - The integration of the Avadel commercial team is expected to enhance the company's presence in sleep medicine, with no immediate overlap with the psychiatry sales force [45][46] Question: Evidence needed for payer reimbursement for both drugs - Management believes that both orexin agonists and oxybates will serve different patient needs, and data will be generated to support reimbursement for both [48][49] Question: Internal bar for ESS in LUMRYZ phase 3 - Management expects the data from the IH study to mirror previous successful programs, with key secondaries being important for prescriber confidence [54][58] Question: Current understanding of NT1 vs NT2 and IH dynamics - The company acknowledges a significant unmet need in the IH market and plans to wait for phase 2 data before initiating phase 3 discussions with the FDA [60][63] Question: Plans to study LUMRYZ with oxybate - Management sees potential benefits for patients using both treatments and plans to build evidence for reimbursement purposes [67][69] Question: Field force strategy for LUMRYZ - The current sales force is deemed right-sized to target the oxybate-eligible patient segment, with ongoing monitoring of market dynamics [72][74] Question: SG&A spend beyond 2026 - Management indicated that one-time transaction costs will not carry over, and future spending will be controlled with potential synergies from the Avadel acquisition [76][78]

Financial Data and Key Metrics Changes - In 2025, Alkermes generated total revenues of nearly $1.5 billion, with a year-over-year growth of 9% in proprietary product sales, amounting to approximately $1.2 billion in net sales [7][8] - The company recorded GAAP net income of $241.7 million, EBITDA of $285.6 million, and adjusted EBITDA of $394 million for the year [10] - For 2026, total revenues are expected to be in the range of $1.73 billion to $1.84 billion, driven primarily by proprietary product net sales projected between $1.52 billion and $1.6 billion [12] Business Line Data and Key Metrics Changes - VIVITROL net sales for 2025 were $467.9 million, reflecting a 2% growth year-over-year, with expectations for 2026 net sales in the range of $460 million to $480 million [22][23] - ARISTADA net sales were $370 million in 2025, showing a 7% growth year-over-year, with projected 2026 net sales between $365 million and $385 million [24][25] - Bupropion net sales grew 24% year-over-year to $346.7 million in 2025, with expectations for 2026 net sales in the range of $380 million to $400 million [26] Market Data and Key Metrics Changes - LUMRYZ, launched in 2023, generated approximately $279 million in net sales in 2025, with a significant opportunity to expand the patient base as there are an estimated 50,000 oxybate-eligible patients with narcolepsy [27][29] - The company expects LUMRYZ total revenue for 2026 to be in the range of $350 million to $370 million, with an additional $315 million to $335 million expected for the remainder of the year following the acquisition of Avadel [29] Company Strategy and Development Direction - The acquisition of Avadel is seen as a strategic milestone, enhancing Alkermes' entry into the commercial sleep medicine market and providing a platform for the potential launch of alixorexton [4][11] - The company plans to advance its orexin portfolio, including alixorexton, which is expected to enter Phase 3 trials for narcolepsy, and develop ALKS 7290 and ALKS 4510 for ADHD and fatigue associated with neurodegenerative disorders [5][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong financial position and the potential for growth in 2026, emphasizing operational discipline and efficient capital allocation [20][21] - The management team highlighted the importance of the upcoming Phase 3 trials for alixorexton and the integration of Avadel's commercial capabilities as key drivers for future success [30][37] Other Important Information - The company ended 2025 with $1.3 billion in cash and total investments, positioning it well for future growth and debt management following the acquisition [11] - Management announced a leadership transition, with Blair Jackson set to take over as CEO, indicating a commitment to continue the company's growth trajectory [37] Q&A Session Summary Question: Regarding the Phase 3 trial design and AE profile - Management indicated that the orexin 2 receptor agonists have a favorable AE profile and that the split dosing is designed to maximize efficacy while minimizing side effects [41][42] Question: Potential synergies between sales forces post-Avaldel acquisition - Management expressed excitement about the integration of the Avadel team and noted that while there is currently little overlap, future synergies are anticipated as the company prepares to launch alixorexton [44][45] Question: Evidence needed for payers to reimburse both oxybates and orexin agonists - Management explained that both treatments may be necessary for certain patients, and they plan to generate data to support the use of both medications [47][48] Question: Internal benchmarks for ESS in the LUMRYZ Phase 3 trial - Management stated that they expect the data from the upcoming study to mirror previous successful profiles and emphasized the importance of secondary endpoints [52][56] Question: Development plans for Valiloxybate - Management indicated that they are moving forward aggressively with Valiloxybate and will assess the need for additional studies based on early data [84][85]

Fourth Quarter and Year-End 2025 Financial Results & Business Update February 25, 2026 Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkermes plc's (the "Company") expectations with respect to its current and future financial, commercial and operating performance, ...

Financial Performance & Acquisition - Alkermes' commercial business generated revenues exceeding $1.45 billion in 2025, demonstrating strong cash flow and profitability[5] - The planned acquisition of Avadel is expected to augment revenue growth and enhance profitability in 2026[5, 46] - LUMRYZ has generated over $390 million in net revenues since its launch as of September 30, 2025[49] Alixorexton Development Program - Alixorexton has blockbuster potential in narcolepsy and idiopathic hypersomnia and was granted FDA Breakthrough Therapy designation in NT1, with Phase 3 initiation planned for Q1 2026[5] - Phase 2 Vibrance-1 study showed statistically significant improvements in mean sleep latency and excessive daytime sleepiness, with clinically meaningful improvements in weekly cataplexy rates in NT1 patients[16] - Phase 2 Vibrance-2 study demonstrated clinically meaningful improvements in wakefulness and excessive daytime sleepiness in NT2 patients[19] Market Opportunity & Pipeline Expansion - The orexin 2 receptor agonist class represents a potential multi-billion dollar market opportunity in narcolepsy and idiopathic hypersomnia[9] - The oxybate market for narcolepsy and idiopathic hypersomnia generated over $1.8 billion in revenues in 2024[11] - Approximately 80,000 narcolepsy patients are treated, with 80% reporting residual symptoms[11] - Alkermes is planning a Phase 2 study of ALKS 4510 in 2026 for fatigue associated with multiple sclerosis and Parkinson's Disease, with a prevalence of approximately 1 million patients each in the US[40]

Core Insights - Avadel Pharmaceuticals plc (NASDAQ:AVDL) is recognized as a promising small-cap stock following its recent financial performance and product developments [1][2]. Financial Performance - In Q3 2025, Avadel reported a revenue increase of 54.86% year-over-year, reaching $77.47 million, which exceeded analysts' expectations by $3.89 million [2]. - The company reported a net income of $20,000 for the quarter, a notable improvement from a net loss of $2.6 million in the same quarter the previous year, which translates to a negative EPS of $0.03 [3]. - The revenue growth was primarily driven by strong sales of LUMRYZ, with a 48% increase in patients using the drug, totaling 3,400 patients as of September 30, 2025 [2][3]. Product Information - Avadel Pharmaceuticals specializes in developing extended-release drug formulations, with its flagship product being LUMRYZ, an FDA-approved therapy for excessive daytime sleepiness in narcolepsy patients [4].

Core Insights - Avadel Pharmaceuticals reported a significant increase in patient enrollment for LUMRYZ, with approximately 3,400 patients treated as of September 30, 2025, representing a 48% increase from the previous year [1] - The company announced a global settlement with Jazz Pharmaceuticals, resolving all litigation and allowing Avadel to commercialize LUMRYZ for additional indications starting March 1, 2028 [9] - Alkermes is set to acquire Avadel for a total transaction value of approximately $2.1 billion, with the deal expected to close in the first quarter of 2026 [2][3] Financial Performance - Avadel generated $77.5 million in net product revenue from LUMRYZ in Q3 2025, marking a 55% increase from $50.0 million in Q3 2024 [10] - Gross profit for Q3 2025 was $81.6 million, or 105% of net product revenue, compared to $43.9 million, or 88% of net product revenue, in the same period of 2024 [11] - Research and development expenses surged to $27.0 million in Q3 2025, up from $3.8 million in Q3 2024, primarily due to upfront license fees related to valiloxybate [12] Corporate Developments - The REVITALYZ™ study, a Phase 3 trial for LUMRYZ, is on track for patient enrollment completion by the end of 2025 [6] - Avadel has strengthened its sleep medicine portfolio by acquiring an exclusive license for valiloxybate from XWPharma, with an upfront payment of $15 million made in Q3 2025 [7] - The company presented new data at World Sleep 2025 supporting LUMRYZ's efficacy in treating narcolepsy across various patient segments [8] Settlement with Jazz Pharmaceuticals - The settlement agreement with Jazz includes the dismissal of lawsuits and upfront cash consideration for Avadel, along with royalty rights for Jazz on LUMRYZ sales from October 1, 2025, to February 18, 2036 [9]